163 related articles for article (PubMed ID: 37841635)
1. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study.
McCarter KR; Wolfgang T; Arabelovic S; Wang X; Yoshida K; Banasiak EP; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Lancet Rheumatol; 2023 May; 5(5):e274-e283. PubMed ID: 37841635
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
3. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study.
Figueroa-Parra G; Gilbert EL; Valenzuela-Almada MO; Vallejo S; Neville MR; Patel NJ; Cook C; Fu X; Hagi R; McDermott GC; Dilorio MA; Masto L; Vanni KMM; Kowalski E; Qian G; Zhang Y; Wallace ZS; Duarte-García A; Sparks JA
Lancet Rheumatol; 2022 Nov; 4(11):e765-e774. PubMed ID: 36118532
[TBL] [Abstract][Full Text] [Related]
4. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.
Juge PA; Hayashi K; McDermott GC; Vanni KMM; Kowalski E; Qian G; Bade K; Saavedra A; Dieudé P; Dellaripa PF; Doyle TJ; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152312. PubMed ID: 38056314
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
11. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
12. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.
Wei J; Choi HK; Dalbeth N; Li X; Li C; Zeng C; Lei G; Zhang Y
JAMA Netw Open; 2023 Aug; 6(8):e2330885. PubMed ID: 37624597
[TBL] [Abstract][Full Text] [Related]
13. Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology-European League Against Rheumatism classification criteria.
Jha I; McMahon GA; Perugino CA; Katz G; Wallace ZS; Fernandes A; Jiang B; Zhang Y; McMahon AE; Guy TV; Liu H; Hernandez-Barco YG; Pillai S; Stone JH
Lancet Rheumatol; 2024 May; ():. PubMed ID: 38824935
[TBL] [Abstract][Full Text] [Related]
14. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis.
Kim ST; Pundole X; Dadu R; Lambotte O; Ramos-Casals M; Suarez-Almazor ME
Immunotherapy; 2021 Apr; 13(6):465-475. PubMed ID: 33641345
[TBL] [Abstract][Full Text] [Related]
15. Weight Change During the Early Rheumatoid Arthritis Period and Risk of Subsequent Mortality in Women With Rheumatoid Arthritis and Matched Comparators.
Sparks JA; Chang SC; Nguyen US; Barbhaiya M; Tedeschi SK; Lu B; Kreps DJ; Costenbader KH; Zhang Y; Choi HK; Karlson EW
Arthritis Rheumatol; 2018 Jan; 70(1):18-29. PubMed ID: 29193837
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
Raaschou P; Simard JF; Holmqvist M; Askling J;
BMJ; 2013 Apr; 346():f1939. PubMed ID: 23568792
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
[TBL] [Abstract][Full Text] [Related]
19. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.
Pratt AG; Siebert S; Cole M; Stocken DD; Yap C; Kelly S; Shaikh M; Cranston A; Morton M; Walker J; Frame S; Ng WF; Buckley CD; McInnes IB; Filer A; Isaacs JD
Lancet Rheumatol; 2021 May; 3(5):e337-e346. PubMed ID: 33928262
[TBL] [Abstract][Full Text] [Related]
20. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
